secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-06-04T21:20:09+00:00
Accession:  0001437749-26-019576
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals closes $22.3M public offering of common stock at $3.50/share
--------------------------------------------------------------------------------

- Priced 5,714,286 shares at $3.50; underwriters' option for 857,142 shares exercised, gross proceeds $22.3M.
- Net proceeds estimated ~$21.6M after underwriting discounts and expenses; funds working capital and growth.
- BTIG acted as lead bookrunner; Lucid Capital Markets as joint bookrunner.
- Offering led by B Group Capital, with participation from Columbia Threadneedle, Corbets Capital, Venture 76, and Mossrock Capital.
- Shares issued under effective S-3 shelf (No. 333-288205); closed June 4, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/0001437749-26-019576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/nrxp20260603_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer